{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=26",
    "query": {
      "condition": "Pharmacokinetics and Pharmacodynamics",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 2339,
    "total_pages": 234,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T13:29:01.739Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04380324",
      "title": "A Study of NKTR-358 (LY3471851) in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "LY3471851",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nektar Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2017-03-19",
      "completion_date": "2019-01-20",
      "has_results": false,
      "last_update_posted_date": "2023-11-18",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04380324"
    },
    {
      "nct_id": "NCT01002950",
      "title": "Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dry Age-related Macular Degeneration",
        "Geographic Atrophy"
      ],
      "interventions": [
        {
          "name": "ACU-4429",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kubota Vision Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 72,
      "start_date": "2009-10",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2014-03-11",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Fort Meyers",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01002950"
    },
    {
      "nct_id": "NCT05904496",
      "title": "A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "BGB-30813",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeiGene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2023-07-19",
      "completion_date": "2025-08-20",
      "has_results": false,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 3,
      "location_summary": "Hackensack, New Jersey • Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05904496"
    },
    {
      "nct_id": "NCT00882180",
      "title": "Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ALN-VSP02",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alnylam Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2009-03",
      "completion_date": "2011-08",
      "has_results": false,
      "last_update_posted_date": "2011-08-24",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 7,
      "location_summary": "Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00882180"
    },
    {
      "nct_id": "NCT00712322",
      "title": "A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neurogenic Detrusor Overactivity"
      ],
      "interventions": [
        {
          "name": "Darifenacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Warner Chilcott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "15 Years",
        "sex": "ALL",
        "summary": "2 Years to 15 Years"
      },
      "enrollment_count": 35,
      "start_date": "2008-10-07",
      "completion_date": "2013-05-23",
      "has_results": true,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00712322"
    },
    {
      "nct_id": "NCT02694822",
      "title": "AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Cancers",
        "Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies"
      ],
      "interventions": [
        {
          "name": "Zalifrelimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agenus Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2016-04",
      "completion_date": "2022-03-31",
      "has_results": true,
      "last_update_posted_date": "2025-03-17",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 11,
      "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02694822"
    },
    {
      "nct_id": "NCT00920257",
      "title": "A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "GSK2141795",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 77,
      "start_date": "2009-06-16",
      "completion_date": "2013-04-17",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 6,
      "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 3 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00920257"
    },
    {
      "nct_id": "NCT02540356",
      "title": "Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites"
      ],
      "interventions": [
        {
          "name": "BAX69 Single-Route Arm",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BAX69 Double-Route Arm",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 2,
      "start_date": "2015-11-02",
      "completion_date": "2016-05-26",
      "has_results": true,
      "last_update_posted_date": "2021-01-12",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 6,
      "location_summary": "Miami, Florida • Augusta, Georgia • Silver Spring, Maryland + 3 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02540356"
    },
    {
      "nct_id": "NCT01380756",
      "title": "Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Hematologic Malignancies",
        "Leukemia",
        "Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Arm 1- Dose Escalation",
          "type": "DRUG"
        },
        {
          "name": "Arm 2- Dose Expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2011-10-04",
      "completion_date": "2014-09-04",
      "has_results": false,
      "last_update_posted_date": "2017-11-06",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 3,
      "location_summary": "Stony Brook, New York • Cleveland, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01380756"
    },
    {
      "nct_id": "NCT01389895",
      "title": "Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cutaneous Lupus",
        "Lupus"
      ],
      "interventions": [
        {
          "name": "AMG 557",
          "type": "DRUG"
        },
        {
          "name": "AMG 557 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 1,
      "start_date": "2011-10",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2014-01-10",
      "last_synced_at": "2026-10-16T13:29:01.739Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01389895"
    }
  ]
}